Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
22 Apr 24
6-K
Report of Foreign Private Issuer
16 Apr 24
6-K
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
11 Apr 24
6-K
Report of Foreign Private Issuer
29 Mar 24
6-K
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
7 Feb 24
6-K
Report of Foreign Private Issuer
22 Jan 24
6-K
Report of Foreign Private Issuer
17 Jan 24
6-K
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
20 Dec 23
6-K
Condensed Consolidated Financial Statements
9 Nov 23
6-K
Report of Foreign Private Issuer
7 Nov 23
6-K
Report of Foreign Private Issuer
2 Nov 23
6-K
Report of Foreign Private Issuer
26 Oct 23
6-K
Report of Foreign Private Issuer
18 Sep 23
6-K
Notice of Annual General Meeting of Shareholders
13 Sep 23
6-K
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
11 Sep 23
6-K
Condensed Consolidated Financial Statements
1 Sep 23
6-K
Report of Foreign Private Issuer
2 Aug 23
6-K
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
31 Jul 23
6-K
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
26 Jun 23
6-K
Condensed Consolidated Financial Statements
16 Jun 23
6-K
Report of Foreign Private Issuer
31 May 23
6-K
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to
8 May 23
6-K
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
19 Apr 23
6-K
Enlivex Appoints Andrew Singer to its Board of Directors
17 Apr 23
20-F
2022 FY
Annual report (foreign)
10 Apr 23
6-K
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
4 Apr 23
6-K
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
3 Apr 23
6-K
Report of Foreign Private Issuer
31 Mar 23
6-K
Report of Foreign Private Issuer
20 Mar 23
6-K
Report of Foreign Private Issuer
23 Feb 23
6-K
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to
15 Feb 23
6-K
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
25 Jan 23
6-K
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
4 Jan 23
6-K
Report of Foreign Private Issuer
30 Dec 22
424B5
Prospectus supplement for primary offering
30 Dec 22
6-K
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
5 Dec 22
6-K
Condensed Consolidated Financial Statements
2 Dec 22
6-K
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
28 Nov 22
6-K
Report of Foreign Private Issuer
15 Nov 22
6-K
Notice of Annual General Meeting of Shareholders
5 Oct 22
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Enlivex Therapeutics Ltd.
9 Sep 19
SC 13G
Enlivex Therapeutics Ltd.
27 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
19 Jun 19
SC 13D
Enlivex Therapeutics Ltd.
31 May 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 18
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 18
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 17
SC 13G/A
Bioblast Pharma Ltd.
10 Jan 17
SC 13G
Bio Blast Pharma LTD.
23 Mar 16
SC 13G/A
Bio Blast Pharma LTD.
12 Feb 16
SC 13G
Bio Blast Pharma LTD.
17 Feb 15
SC 13G
Bio Blast Pharma LTD.
17 Feb 15
SC 13G
Bio Blast Pharma LTD.
17 Feb 15
SC 13G/A
Bio Blast Pharma LTD.
13 Feb 15
SC 13G
Bio Blast Pharma LTD.
17 Oct 14
SC 13G
Bio Blast Pharma LTD.
11 Aug 14